Akoya Biosciences Inc

Akoya Biosciences — Investor Presentation (June 2023)

26 slides from Akoya Biosciences's investor presentation, Jun 7, 2023

  1. Slide 1: Investor Presentation June 2023

    Investor Presentation June 2023

  2. Slide 2: Akoya Disclaimer

    2 Akoya Disclaimer Disclaimer Akoya Biosciences, Inc. (the "Company") has filed a registration statement (including a preliminary prospectus supplement and an accompanying prospectus) with the Securities Exchange Commission ("SEC") for the offering to which this communication relates. Before you inv

  3. Slide 3: Akoya is Leading the Spatial Biology Revolution

    3 Akoya is Leading the Spatial Biology Revolution Complete end-to-end solutions Instruments, reagents, software & services Established market leader with largest installed base ~1,000 instruments installed worldwide Greatest number of high-impact publications 860+ total publications Transforming Dis

  4. Slide 4: Driving Towards a Deeper Understanding of Biology

    4 Driving Towards a Deeper Understanding of Biology Advancing Next Generation Tissue Analysis DNA RNA Protein Translation Transcription Reverse Transcription Understanding disease progression & response to therapy requires UNBIASED mapping of tissue architecture

  5. Slide 5: Akoya is Transforming Tissue Analysis

    5 Akoya is Transforming Tissue Analysis Mapping Whole Tissue Unlocks an Understanding of Disease Progression & Response to Therapy The LOCATION of key cell types, proteins & transcripts drives tumor activity & immune response Single-Cell Resolution Subcellular Resolution Single-Section Whole Slide C

  6. Slide 6: Meeting an Unmet Medical Need in Immunotherapy

    What is next? High >80% Low <5% Ideal predictive power Response to immunotherapy in solid tumors Tumor Mutational Burden (TMB) High TMB ~40% Low TMB ~20% Limited predictive power Response to immunotherapy in solid tumors3 Meeting an Unmet Medical Need in Immunotherapy 6 1 Lu S, Stein JE, Rimm DL, et

  7. Slide 7: Akoya Enables Complete End-to-End Spatial Solutions

    Biomarker Discovery High multi-plex panels Biomarker Validation Targeted panels Translational / Clinical Use Large-scale studies Akoya Enables Complete End-to-End Spatial Solutions 7 Owning the Spatial Biomarker Journey – Discover, Validate & Deploy PhenoCycler-Fusion PhenoImager Fusion PhenoImager

  8. Slide 8: Largest & Rapidly Growing Installed Base

    8 Largest & Rapidly Growing Installed Base Adoption Across Discovery, Translational & Clinical Markets 273 PhenoCyclers 149 PhenoImager Fusions 570 PhenoImager HTs, Mantras & Vectras Installed base of 1000+ instruments1 550 697 934 992 FY 2020 FY 2021 FY 2022 Q1 2023 1 1,000th instrument shipped in

  9. Slide 9: Akoya's Accelerating & Market Leading Publication Volume

    9 Akoya’s Accelerating & Market Leading Publication Volume Spatial Biology is Driving Major Discoveries Across Multiple Therapeutic Areas 860+ total publications featuring Akoya’s platforms 196 493 772 860 FY 2020 FY 2021 FY 2022 Q1 2023

  10. Slide 10: Immediate Opportunity in Discovery & Translational Markets

    Immediate Opportunity in Discovery & Translational Markets With Clinical Rapidly Emerging Clinical $7B Translational $4B Discovery $3B Akoya is meeting customer & market segment requirements to drive market expansion Speed Whole Slide 10 Robustness and Utility Estimated Total Addressable Market (TAM

  11. Slide 11: Drivers of Spatial Biology Market Growth Over Next Years

    11 Drivers of Spatial Biology Market Growth Over Next 5 Years *DeciBio Spatial Biology Market Report First Edition: Q4 2022; November 7, 2022 • Spatial biology market will grow 30% annually in the next 5 years • Translational & clinical research to make up the largest market segment • Routine clinic

  12. Slide 12: Setting the Standard in Spatial Biology

    Setting the Standard in Spatial Biology Akoya Consistently Leads in Meeting Spatial Biology Market Requirements 2019-20 12 2021-22 2023+ Single-Cell Whole Slide In Situ Imaging Fastest Spatial Scalability Biology System Accelerated Workflow & Application Expansion Simplicity

  13. Slide 13: Akoya's Spatial Biology Workflow

    Akoya’s Spatial Biology Workflow 13 Rapid Menu Expansion • Ready-to-use panels & increasing plex • New applications • Consistent chemistries PROBE AND STAIN IMAGE ANALYZE Improved Workflows • Continuous speed improvements • Workflow simplification • Consistent imaging methods Flexible Data Analysis

  14. Slide 14: Introducing PhenoCode Panels

    14 • High-plex protein panels • Focus on oncology, inflammatory disease & neurobiology markers • Ready-to-use panels & modules • High-plex panels enable unbiased & comprehensive discovery experiments • Increased pull through & accelerated time to answer Introducing PhenoCode™ Panels Delivering a Sui

  15. Slide 15: PhenoCode Discovery Panels

    15 PhenoCode™ Discovery Panels PhenoCode™ Discovery Panels for Comprehensive Coverage High-Plex Panels for Biomarker Discoveries Across Multiple Research Verticals Immune Cell Profiling Core Immune Checkpoints & Activation Stress & Signaling Response Tumor & Tissue Specific Markers Metabolism Advanc

  16. Slide 16: PhenoCode Signature Panels

    16 PhenoCode™ Signature Panels Immune Profile Immuno-contexture Activated TIL Status M1/M2 Polarization Exhaustion PhenoCode™ Signature Panels for Immuno-Oncology 5 Customizable Panels Focused on Key Clinical Questions

  17. Slide 17: PhenoCycler-Fusion Journey

    17 PhenoCycler-Fusion Journey PhenoCycler • 50 plex • 2 samples / week • Required 3rd party microscope 2019-20 2021-22 2023 Enabling Higher Plex, Menu Expansion, Faster Workflows & Scaled Experiments PhenoCycler-Fusion 1.0 • 75 plex • 10+ samples / week • Real time data compression PhenoCycler-Fusio

  18. Slide 18: PhenoImager HT Journey

    18 PhenoImager HT Journey 2019-20 2021-22 2023 Translating Discoveries to the Clinic & Building the Foundations for Diagnostics • 6+ plex customer designed • 300 samples / week • ISO & quality systems • MITRE study published • ABS launched • CLIA certified • 6+ plex ready-to-use • Biopharma CDx part

  19. Slide 19: Data Analysis Ecosystem Across Akoya's Workflows

    19 Data Analysis Ecosystem Across Akoya’s Workflows QuPath Flexible Open Source Leading Analysis Service Providers Powerful High-Plex Analysis in the Cloud Machine Learning & AI Data standardization enables a growing software ecosystem Accessibility to cutting-edge analysis Software partnerships pro

  20. Slide 20: Evolving to Realize Our Clinical Aspirations

    20 Evolving to Realize Our Clinical Aspirations From life sciences tools company to a medical company From imaging platform to diagnostic platform From scientist to clinician Commercial Product Market

  21. Slide 21: OncoSignature CDx - New Era of Precision Medicine

    OncoSignature® CDx - New Era of Precision Medicine 21 ADVANCED BIOPHARMA SOLUTIONS (ABS) CDx assay developed on PhenoImager HT OncoSignature® test, a spatial signature CDx assay Patient screened using OncoSignature® test to identify responders to ACR-368 Pending FDA approval, results of OncoSignatur

  22. Slide 22: Partnering to Accelerate Clinical Spatial Biology Adoption

    Partnering to Accelerate Clinical Spatial Biology Adoption 22 End-to-End Commercial Workflow - Reagents, Staining, Imaging, Analysis & Services • Industry leading multi-plex imager • Translational and clinical multiplexing expertise • CLIA lab capabilities • IVD approved workflow • Established marke

  23. Slide 23: Qualified CRO Service Provider Network

    23 Qualified CRO Service Provider Network • To support and guide drug development programs, spatial phenotyping techniques using Akoya’s platforms can be accessed through our global network of qualified CRO service providers • Each provider has completed a qualification process designed for evaluati

  24. Slide 24: Akoya's Strategic Priorities

    Akoya’s Strategic Priorities 24 Driving Operational Leverage, Gross Margin Improvements and Advancing our Portfolio • Expand menu of applications • Platform improvements drive throughput • Streamline data analysis & time to answer Accelerate Pull Through • Drive translational adoption – leveraging C

  25. Slide 25: Financial Overview

    25 Financial Overview Recurring revenue model Recurring reagent revenue from global installed base Expanding lab services with key biopharma partners Consistent growth profile Ahead of consensus every quarter since IPO Increasing menu content, pull through & clinical partnerships Well-capitalized to

  26. Slide 26: Catalyzing Discovery & Improving Patient Care

    Catalyzing Discovery & Improving Patient Care

Akoya Biosciences — Investor Presentation (June 2023) on 6ix